Compare PDLB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | ADCT |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.9M | 483.1M |
| IPO Year | 2017 | 2020 |
| Metric | PDLB | ADCT |
|---|---|---|
| Price | $16.95 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 105.7K | ★ 2.0M |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.83 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $96,252,000.00 | $75,209,000.00 |
| Revenue This Year | $10.97 | $10.36 |
| Revenue Next Year | $8.59 | $3.87 |
| P/E Ratio | $19.13 | ★ N/A |
| Revenue Growth | ★ 26.04 | 6.35 |
| 52 Week Low | $10.88 | $1.05 |
| 52 Week High | $18.01 | $4.80 |
| Indicator | PDLB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 45.74 |
| Support Level | $17.09 | $3.56 |
| Resistance Level | $17.80 | $4.28 |
| Average True Range (ATR) | 0.44 | 0.43 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 62.13 | 48.51 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).